The Plasminogen Activator Inhibitor 1 4G/5G Polymorphism and the Risk of Alzheimer's Disease.

ABSTRACT:

Objective

The aim of this study was to determine whether plasminogen activator inhibitor 1 (PAI-1) is associated with the risk of Alzheimer's disease (AD) in Tunisian patients.

Design and methods

We analyzed the genotype and allele frequency distribution of the PAI-1 polymorphism in 60 Tunisian patients with AD and 120 healthy controls.

Results

The results show a significantly increased risk of AD in carriers of the 4G/4G and 4G/5G genotypes versus the wild-type 5G/5G genotype (4G/4G: 28.33% in patients vs 10.0% in controls; P < 10^-3; OR = 8.78; 4G/5G: 55.0% in patients vs 38.33% in controls; OR = 4.45; P < 10^-3). The 4G allele was also more frequently found in patients compared with controls; P < 10^-3; OR = 3.07. For all participants

SUBMITTER: Fekih-Mrissa N 

PROVIDER: S-EPMC10852582 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature